MYOS Announces Distribution Partnership for Their Blockbuster Canine Muscle Formula with Chewy, a Leading Online Retailer of Pet Food and Pet-Related Products

CEDAR KNOLLS, N.J., Jan. 30, 2020 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), a bionutrition company and the owner of Fortetropin^®, a proprietary bioactive composition made from fertilized egg yolk that helps build lean muscle, announced today that it has entered into a distribution agreement with Chewy (www.chewy.com), a leading online retailer of pet food and pet-related products.  Chewy will distribute MYOS Canine Muscle Formula^®, an advanced nutrition product that has been clinically shown to increase muscle mass, prevent atrophy of disuse and improve recovery from injuries in canines. This study was conducted at Kansas State University involving 100 dogs.

"We are delighted to be partnering with Chewy to distribute MYOS Canine Muscle Formula to pet owners across the United States," stated Joseph Mannello, CEO, MYOS RENS Technology.  "Chewy is a leading online retailer of pet food and pet-related products in the U.S. They distribute products of the highest quality and provide outstanding customer service.  We feel honored that MYOS Canine Muscle Formula will be distributed alongside leading brands in the pet food and pet nutrition market," added Mr. Mannello.

In 2019, MYOS announced at the North American Veterinary Conference in Orlando, FL that dogs that consumed MYOS Canine Muscle Formula following tibial plateau leveling osteotomy (TPLO) surgery to repair tears of the cranial cruciate ligament (CCL), experienced reduced muscle atrophy and improved recovery after 8 weeks following surgery when compared with dogs that received a macronutrient-matched placebo.  Following the announcement of results from this study, MYOS announced the initiation of another clinical study at Kansas State University to examine the impact of MYOS Canine Muscle Formula on quality of life and activity in geriatric dogs.

In addition to the Company's distribution partnership with Chewy, its products for the Canine Health Market are available direct-to-consumer at www.myospet.com and at Amazon.com.

About MYOS RENS Technology Inc.
MYOS RENS Technology Inc. (MYOS), "The Muscle Company^®", is a Cedar Knolls, NJ-based advanced nutrition company that develops and markets products that improve muscle health and performance. MYOS is the owner of Fortetropin^®, a fertilized egg yolk-based product manufactured via a proprietary process to retain and optimize its biological activity. Fortetropin has been clinically shown to increase muscle size, lean body mass and reduce muscle atrophy. MYOS believes Fortetropin has the potential to redefine existing standards of physical health and wellness. For more information, please visit www.myosrens.com.  

About Myos Canine Muscle Formula^®
Myos Canine Muscle Formula (Regular and Veterinarian Strength) is an advanced veterinary health supplement to support muscle health in dogs, featuring Fortetropin as the active ingredient. Fortetropin is made through a patented process that maintains the vital nutrients of fertilized egg yolks to help build more lean muscle and decrease muscle loss.  For more information, please visit www.myospet.com.

Forward-Looking Statements
Any statements in this release that are not historical facts are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the ability to create new products through research and development, the successful results of strategic initiatives, the success of our products, including MYOS Canine Muscle Formula^®,  Physician Muscle Health Formula^®,  Yolked^®,  Qurr^® and MYOS Enteral Nutrition Formula™, the success of our research and development, the results of the clinical evaluation of Fortetropin^® and its effects, the ability to enter into new partnership opportunities and the success of our existing partnerships, the ability to generate revenue and cash flow from sales of our products, the ability to increase our revenue and gross profit margins, the ability to achieve a sustainable, profitable business, the effect of economic conditions, the ability to protect our intellectual property rights, competition from other providers and products, the continued listing of our securities on the Nasdaq Stock Market, risks in product development, our ability to raise capital to fund continuing operations, and other factors discussed from time to time in our filings with  the Securities and Exchange Commission. We undertake no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

Investor Relations:
MYOS RENS Technology
Joanne Goodford
Phone: 973-509-0444
Email:  [email protected]

SOURCE MYOS RENS Technology

Related Links

http://www.myosrens.com